In a phase 2 trial, resmetirom, an agonist for THR-β, resulted in a significant reduction in hepatic fat after 12 weeks and 36 weeks of treatment in patients with NASH [19]. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.